1501P Preliminary analysis of a single-arm, multi-center study of anlotinib combined with toripalimab in first-line treatment of unresectable or metastatic undifferentiated pleomorphic sarcoma

Abstract

Undifferentiated pleomorphic sarcoma (UPS) is one of the common subtypes of soft tissue sarcoma (STS). Alternative therapy is needed for patients who are not suitable for chemotherapy. Antiangiogenic agents are approved for the treatment of advanced STS. In the SARC028 study, PD-1 inhibitor showed initial efficacy on UPS. The combination of antiangiogenic agent and PD-1 inhibitor may have synergistic effects. This single-arm phase II study aims to evaluate the efficacy and safety of anlotinib combined with toripalimab in the first-line treatment of patients with unresectable or metastatic UPS.